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PROTECTION FOR OBESE MALE TYPE 2 DIABETES 
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SUMMARY – The aim of this study was to determine plasma adropin concentration and param-
eters of insulin resistance in obese male type 2 diabetes mellitus (T2DM) patients before and after 
3-month liraglutide treatment. In this interventional study, we enrolled 15 obese male T2DM patients 
with body mass index (BMI) >35 kg/m2, uncontrolled disease and HbA1c >7.5%, having previously 
taken taking two oral antidiabetic drugs. We modified their therapy to metformin and liraglutide for 
the next three months. After three months of liraglutide treatment, we observed significant decrease 
in body weight (from 111.5±18.7 kg to 109.2±17.5 kg, p=0.016) and BMI (from 40.9±7.3 to 40.1±7.0 
kg/m2, p=0.021). Plasma adropin concentration increased significantly (p=0.003) compared with base-
line. Fasting plasma insulin level decreased from 17.79±6.53 to 13.38±3.51 mU/L (p=0.002), fasting 
plasma glucose level decreased from 8.66±3.07 to 7.41±2.21 mmol/L (p=0.004) and HbA1c decreased 
from 7.98±0.70% to 7.26±0.36% (p=0.003). Insulin resistance presented as HOMA-IR decreased 
significantly from 7.30±5.19 to 4.52±2.61 (p=0.002). Systolic blood pressure, lipid status, liver and 
kidney function improved, but not reaching statistical significance. Treating obese male T2DM pa-
tients with liraglutide resulted in a significantly higher plasma adropin concentration, significant 
weight loss and improved parameters of insulin resistance, i.e. decreased fasting plasma insulin, plasma 
glucose levels and HOMA-IR.
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Introduction
Nowadays, type 2 diabetes mellitus (T2DM) seems 
to be one of the most important public health chal-
lenges. Current estimates of its incidence are impre-
cise, only providing a rough picture, and probably un-
derestimating the disease burden1. Dealing with 
T2DM implies coping with the complex chronic dis-
ease that demands lifelong medical and self care in or-
der to prevent acute and delay chronic complications2. 
Body mass index (BMI) has a strong relationship to 
insulin resistance and T2DM development. In obese 
individuals, the amount of substances involved in the 
development of insulin resistance is increased. The 
pathogenesis of T2DM development is based on the 
fact that pancreatic β-cells are impaired, causing a lack 
of blood glucose control. The development of T2DM 
becomes inevitable if the pancreatic β-cell failure is 
 accompanied by insulin resistance3. T2DM increases 
overall mortality primarily due to cardiovascular dis-
ease, which is the major cause of morbidity and mor-
tality among these patients. Further on, patients with 
poor glycemic control are at risk of developing micro- 
and macrovascular complications, unlike those who 
maintain tight glycemic control4,5.
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Ten years ago, Kumar et al. identified a new protein 
named adropin, which is believed to play an important 
role in metabolic homeostasis, insulin resistance pre-
vention, dyslipidemia and impaired glucose toler-
ance6-8. It is encoded by the ENHO gene (Energy Ho-
meostasis Associated Gene) and its expression in the 
liver, heart, brain and coronary arteries is diet depen-
dent6. Results of the studies conducted so far show 
that the diseases resulting from metabolic syndrome, 
such as obesity, T2DM, non-alcoholic fatty liver dis-
ease, polycystic ovary syndrome, or cardiovascular dis-
ease are accompanied by significant changes in the 
concentration of this peptide8. Plasma adropin con-
centration is decreased in T2DM patients, especially 
those overweight or obese9,10. Moreover, adropin is a 
potent regulator of cardiovascular function and plays a 
protective role in the pathogenesis and development of 
cardiovascular disease11. It regulates endothelial cell 
function and its plasma concentration has been found 
to be lower in individuals with endothelial dysfunc-
tion, which seems to be an autonomous indicator of 
cardiovascular incidents in individuals with T2DM. 
Furthermore, adropin concentration and HbA1c are 
shown to be independent risk factors for endothelial 
dysfunction in these patients12-14.
Diabetes mellitus type 2 is characterized by a re-
duced incretin effect and inappropriate glucagon lev-
els, so the incretin-based therapy could provide benefi-
cial effects, not only because of the antidiabetic effect 
but also for the favorable effect on body weight15,16. In 
2010, the National Institute for Health and Care Ex-
cellence (NICE) issued guidance on the use of one of 
the incretins called liraglutide in T2DM17. Liraglutide 
is an analog of human glucagon-like peptide-1 (GLP-
1) and acts as GLP-1 receptor agonist (GLP-1 RA). 
Its efficacy in glycemic control has already been estab-
lished. It increases insulin and reduces glucagon secre-
tion, slows down gastric emptying, postpones carbohy-
drate absorption, and augments satiety18,19. The major-
ity of T2DM patients on liraglutide treatment report 
more significant weight loss than those treated with 
other GLP-1 RA20. To assess the long-term effects of 
liraglutide on cardiovascular outcomes and clinically 
important events, the Liraglutide Effect and Action in 
Diabetes: Evaluation of Cardiovascular Outcome Re-
sults (LEADER) trial was initiated in 201021. Trial 
results showed a lower rate of death from cardiovascu-
lar causes, nonfatal myocardial infarction, or nonfatal 
stroke among T2DM patients treated with liraglutide 
as compared to those on placebo22.
Considering the fact that T2DM patients are char-
acterized with lower plasma adropin concentration9 
and that liraglutide has a positive effect on both glyce-
mic control and cardiovascular outcomes20-22, we de-
cided to explore plasma adropin concentration in obese 
T2DM patients after three months of liraglutide 
treatment. As far as we know, this is the first report on 
adropin concentration in obese T2DM patients un-
dergoing liraglutide treatment.
The aim of this study was to determine plasma 
adropin concentration and parameters of insulin resis-
tance in male obese T2DM patients before and after 
3-month liraglutide treatment.
Materials and Methods
This was a non-randomized, controlled, interven-
tional study. The primary objective was to determine 
plasma adropin concentration and parameters of insu-
lin resistance in male obese T2DM patients before and 
after three months of liraglutide treatment. Patients 
treated at Department of Endocrinology and Diabe-
tes, Split University Hospital Centre from April 2017 
to June 2017 were invited to participate in the study. 
Investigators had meetings with patients and explained 
the study nature, aim, potential hazards, and expected 
outcomes. The study was conducted according to the 
Declaration of Helsinki and Good Clinical Practice, 
with a written informed consent  obtained from each 
participant. It was approved by Ethics Committee of 
the Split University Hospital Centre. Sampling was 
performed in 15 male obese T2DM patients with 
BMI >35 kg/m2, uncontrolled diabetes mellitus and 
HbA1c >7.5%. All the participants had previously re-
ceived two oral antidiabetic drugs. In all cases, first-
line agent was metformin, while second-line agent was 
sulfonylurea in 12 and dipeptidyl peptidase-4 (DPP-4) 
inhibitor in three participants. In our study, we modi-
fied their therapy, which now consisted of metformin 
(1000 mg b.i.d.) and liraglutide (Victoza®, Novo Nor-
disk A/S, Bagsvaerd, Denmark) for the next three 
months. To improve gastrointestinal tolerability, the 
starting dose was 0.6 mg liraglutide daily. After two 
weeks, the dose was increased to overall 1.2 mg daily 
until the end of the study.
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In each participant, we observed anthropometric 
data, blood pressure, parameters of glucose metabo-
lism, Homeostatic Model Assessment of Insulin Re-
sistance (HOMA-IR) index and plasma adropin con-
centration at the beginning and after three months of 
the study. Anthropometric measurements included 
body height, weight, BMI, body circumferences (waist 
and hip), and waist to hip ratio (WHR). Body height 
was measured using a stadiometer with the investiga-
tor standing behind the participant. Subjects stood 
with their scapula, buttocks and heels resting against 
the stadiometer, the neck was held in a natural non-
stretched position, the heels were touching each other, 
the toe tips formed a 45° angle and the head was held 
straight with the inferior orbital border in the same 
horizontal plane as the external auditive conduct 
(Frankfort’s plane). The horizontal arm of the stadi-
ometer was lowered until it touched the scalp (anthro-
pometric point vertex). Body weight was measured on 
a medical decimal scale with sliding weight, with a 
±250 g error margin. Patients were barefoot, only 
wearing their underwear. The weight was rounded up 
to the nearest 0.5 kg. BMI was estimated by dividing 
weight (kg) by height2 (m2)23-25. Waist and hip circum-
ferences were measured using a flexible non-elastic 
measuring tape. Individuals stood with their feet to-
gether and arms resting by their sides. Hip circumfer-
ence was measured from the maximum perimeter of 
the buttocks. Waist circumference was taken as the 
plane between the umbilical scar and the inferior rib 
border. Each measurement was performed twice and 
the mean result was calculated26,27. Waist circumfer-
ence was used to identify individuals with possible 
health risks based upon threshold values of ≥88 cm for 
women and ≥102 cm for men. WHR measurement is 
used to estimate visceral or android obesity. WHR was 
estimated by dividing waist circumference by hip cir-
cumference. The threshold WHR was ≥0.85 for wom-
en and ≥1.00 for men and was used as a criterion for 
android obesity. Abdominal circumference and WHR 
are good indicators of body fat distribution and car-
dio-metabolic risk27,28. Blood pressure was measured 
using a mercury sphygmomanometer with the corre-
sponding cuff size (Riester desk model), following the 
WHO MONICA Protocol (MONItoring of trends 
and determinants in CArdiovascular disease and Pro-
tocol)29. Patients were seated and relaxed for 5 minutes 
before the measurements were taken. Measurements 
were performed on the right forearm, at the position of 
the brachial artery by trained measurers. Values were 
noted with ±2 mm Hg accuracy. Two measurements 
were done, 5 minutes apart, and the mean value of the 
two measurements was used for analysis30.
According to the regular protocol, the same experi-
enced biochemist took and analyzed blood samples 
obtained from the antecubital vein after 12-hour over-
night fasting. Fasting blood samples were analyzed in 
the same laboratory, using the same method for each 
substance. The biochemist had no knowledge of the 
patient medical condition. Insulin blood levels were 
measured using the electrochemiluminescence immu-
noassays (Roche® Diagnostics GmbH, Mannheim, 
Germany). Enzymatic hexokinase photometric assay 
(Abbott®, Chicago, IL, USA) was used to measure 
fasting plasma glucose and turbidimetric inhibition 
immunoassay (Roche® Diagnostics GmbH, Mann-
heim, Germany) to measure HbA1c plasma levels. 
Plasma adropin levels were measured using an en-
zyme-linked immunosorbent assay kit (Phoenix Phar-
maceuticals, Belmont, CA, USA) according to the 
manufacturer’s instructions. Other laboratory analyses 
were performed according to the standard laboratory 
protocols. Insulin resistance score (HOMA-IR) was 
calculated using the following formula: fasting plasma 
glucose (mmol/L) x fasting serum insulin (µU/mL) 
divided by 22.5.
Statistical analyses were performed using MedCalc 
for Windows, version 11.5.1.0 (MedCalc Software, 
Mariakerke, Belgium) statistical software. Continuous 
variables were expressed as mean ± standard deviation, 
whereas categorical variables were expressed as whole 
numbers and percentages. Differences between base-
line and after three-month treatment values were de-
termined using Wilcoxon matched paired test. The 
level of statistical significance was set at p<0.05.
Results
Fifteen male obese T2DM patients receiving ther-
apy that consisted of metformin (1000 mg b.i.d.) and 
liraglutide (Victoza®, Novo Nordisk A/S, Bagsvaerd, 
Denmark) were followed up for three months. Median 
age of the patients included in our study was 60 years, 
body weight (mean ± standard deviation [SD]) was 
111.5±18.7 kg, BMI (mean ± SD) was 40.9±7.3 kg/m2 
and HbA1c (mean ± SD) was 7.98±0.70%. Baseline 
waist to hip ratio (mean ± SD) was 0.96±0.08.
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After three months of liraglutide treatment, we ob-
served changes in anthropometric parameters (Table 
1). Analysis confirmed a significant decrease in both 
body weight and BMI; body weight was reduced from 
111.5±18.7 kg to 109.2±17.5 kg (p=0.016) and BMI 
from 40.9±7.3 to 40.1±7.0 kg/m2 (p=0.021). Over 
these three months, systolic blood pressure decreased 
but not significantly. After 3-month liraglutide treat-
ment, plasma adropin concentration increased signifi-
cantly (p=0.003) as compared with the baseline (Fig. 
1). Besides obesity reduction, disease control was re-
markably improved. All the parameters of glucose me-
tabolism improved significantly. Fasting plasma insu-
lin level decreased from 17.79±6.53 to 13.38±3.51 
Table 1. Anthropometric data
Variable Baseline* After 3 months of treatment* p***
Age (years)** 60 (55-68) 60 (55-68) 1.000
Body height (cm) 165.5±8.6 165.5±8.9 1.000
Body weight (kg) 111.5±18.7 109.2±17.5 0.016
Body mass index 









Waist to hip ratio 0.96±0.08 0.97±0.08 0.721
Systolic blood 
pressure (mm Hg) 140±11 139.5±9.9 0.767
Diastolic blood 
pressure (mm Hg) 85.9±4.4 87.3±3.4 0.224
*Data presented as mean ± standard deviation (SD); **data pre-
sented as median; ***Wilcoxon matched paired test
Table 2. Glucose metabolism parameters
Variable Baseline After 3 months of treatment p*
Fasting insulin 




8.66±3.07 7.41±2.21 0.004 
HbA1c (%) 7.98±0.70 7.26±0.36 0.003 
HOMA-IR 7.30±5.19 4.52±2.61 0.002 
Data presented as mean ± standard deviation (SD); *Wilcoxon 
matched paired test; HOMA-IR = Homeostatic Model Assess-
ment of Insulin Resistance
Fig. 1. Plasma adropin concentration – baseline and after 
3-month liraglutide treatment.
Table 3. Biochemical parameters
Variable Baseline After 3 months of treatment p*
Triglycerides 
(mmol/L) 1.88±1.34 1.78±1.14 0.449 
Cholesterol 








3.39±0.71 3.26±0.72 0.082 
AST (U/L) 20.4±7.71 21.2±8.12 0.173 
ALT (U/L) 30.6±22.32 31.9±18.65 0.102 
GGT (U/L) 30.70±18.95 29.1±15.75 0.332 
Creatinine 
(µmol/L) 79.09±23.29 81.36±23.91 0.230 
Urea 
(mmol/L) 6.02±1.12 6.05±1.12 0.476 
Urate 
(µmol/L) 398.09±71.98 391.0±67.57 0.104 
Data presented as mean ± standard deviation (SD); *Wilcoxon 
matched paired test: HDL = high-density lipoprotein; LDL = low-
density lipoprotein; AST = aspartate transaminase; ALT = alanine 
transaminase; GGT = gamma-glutamyltransferase
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mU/L (p=0.002), fasting blood glucose level from 
8.66±3.07 to 7.41±2.21 mmol/L (p=0.004) and HbA1c 
from 7.98±0.70 to 7.26±0.36% (p=0.003). Insulin re-
sistance presented as HOMA-IR improved signifi-
cantly and its value decreased from 7.30±5.19 to 
4.52±2.61 (p=0.002) (Table 2).
Our study showed improvement in lipid profile 
(cholesterol, triglycerides, low-density lipoproteins), 
but these results did not show significant change. Ad-
ditionally, we noticed improvement in liver function 
through a decrease of aspartate transaminase (AST), 
alanine transaminase (ALT) and gamma-glutamyl-
transferase (GGT) levels but these results were not 
statistically significant. Kidney function was slightly 
improved, although creatinine, urea and urate levels 
did not show significant change (Table 3).
Discussion
Considering the fact that obesity and insulin resis-
tance play key roles in the development of T2DM, 
therapeutic options leading to the resolution of these 
issues may be of utmost importance3,5,31,32. Identifying 
adropin as a marker of endothelial cell dysfunction 
that is found to be lower in T2DM patients9,10 and that 
liraglutide may afford protection against endothelial 
cell dysfunction, which is an early abnormality in dia-
betic vascular disease33, led us to explore adropin levels 
in T2DM patients treated with liraglutide. Therefore, 
this study is of great importance because it is the first 
one to compare the effects of liraglutide treatment on 
plasma adropin concentration and parameters of insu-
lin resistance in T2DM patients.
Kumar et al. hypothesize that adropin is involved in 
regulation of metabolic homeostasis and that its defi-
ciency has a negative effect on glucose homeostasis 
and carries an increased risk of developing insulin re-
sistance and T2DM progression6-8. Our study provid-
ed data on the effect of 3-month liraglutide treatment 
applied once daily in combination with metformin in 
male obese patients with T2DM. We showed that lira-
glutide treatment led to a significantly higher plasma 
adropin concentration (p=0.003), one of the regulators 
of endothelial cell dysfunction in T2DM12-14. Hence, 
elevated plasma adropin concentration could partially 
explain cardiovascular benefits and protection provid-
ed by liraglutide. Furthermore, the application of lira-
glutide and higher adropin concentration were associ-
ated with decreased insulin resistance parameters. 
Consequently, the levels of fasting plasma glucose 
(p=0.004), fasting plasma insulin (p=0.002) and 
HOMA-IR (p=0.002) decreased significantly after 
three months of liraglutide treatment.
Recent studies demonstrated that patients with 
T2DM treated with GLP-1 RA improved their glyce-
mic control and had modest weight loss34. Other stud-
ies showed that liraglutide treatment significantly de-
creased weight and improved insulin resistance32. Our 
results also confirmed that this treatment led to sig-
nificant weight loss (p=0.016), decreased BMI (p= 
0.021) and improved insulin resistance parameters 
(p=0.002). Decreased adiposity could be the outcome 
of early satiety and slower gastric emptying caused by 
liraglutide20. Following the previous information, not 
only BMI was significantly reduced, but also HbA1c 
(p=0.003), which was shown in previous studies32,34,35.
Furthermore, we observed a small decrease in sys-
tolic blood pressure, but it was not statistically signifi-
cant, unlike several other studies that investigated lira-
glutide effect36,37. Considering the fact that our study 
was shorter (12 weeks) than the mentioned studies (24 
weeks), we think that our results would probably be of 
the same relevance with longer study duration. In ad-
dition to a significantly decreased level of systolic 
blood pressure, liraglutide appears to improve the lev-
els of cholesterol, low-density lipoprotein cholesterol 
and triglycerides20. Our study showed improvement in 
lipid profile (cholesterol, triglycerides, low-density li-
poproteins) and systolic blood pressure, but did not 
demonstrate statistical significance compared to other 
studies. This may be due to the lower baseline BMI 
(33.49±5.15 kg/m2)35 when compared to our patient 
BMI (40.9±7.3 kg/m2).
Another interesting finding was a slight reduction 
in ALT, AST and GGT concentrations. This GGT re-
sult found in our study was similar to the previously 
reported results, but ALT and AST results in our study 
were not in concordance with other studies. These dif-
ferences may have been due to the lower baseline BMI 
level (30.1 kg/m2) and lower body weight in the above-
mentioned study.
Conclusions
In conclusion, treating male obese T2DM patients 
with liraglutide results in a significantly higher plasma 
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adropin concentration, significant weight loss and im-
proved parameters of insulin resistance, i.e. decreased 
fasting plasma insulin and glucose levels and decreased 
HOMA-IR. Liraglutide treatment also ameliorates 
systolic blood pressure, lipid profile and kidney func-
tion, but these results were not statistically significant. 
Additional studies of longer duration and larger num-
ber of participants are needed so we could have more 
precise and reliable results.
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Sažetak
ADROPIN – POTENCIJALNI ČIMBENIK KARDIOVASKULARNE SIGURNOSTI  
U MUŠKARACA OBOLJELIH OD ŠEĆERNE BOLESTI TIP 2 LIJEČENIH LIRAGLUTIDOM
T. Tičinović Kurir, T. Miličević, A. Novak, M. Vilović i J. Božić
Cilj je bio usporediti plazmatske vrijednosti adropina i parametre inzulinske rezistencije kod pretilih muškaraca koji 
boluju od šećerne bolesti tip 2 (ŠBT2) prije i nakon 3 mjeseca primjene liraglutida. U ovoj intervencijskoj studiji sudjelovalo 
je 15 pretilih muškaraca koji boluju od ŠBT2 s indeksom tjelesne mase (ITM) >35 kg/m2, loše reguliranom bolešću i HbA1c 
>7,5%. Ispitanici su prethodno u terapiji imali dva peroralna antidijabetična lijeka. Nakon uključenja u studiju terapija im je 
modificirana na metformin i liraglutid tijekom tri mjeseca. Nakon primjene liraglutida kod ispitanika je zamijećeno smanje-
nje tjelesne mase (sa 111,5±18,7 na 109,2±17,5 kg, p=0,016) i ITM (s 40,9±7,3 na 40,1±7,0 kg/m2, p=0,021), dok su plaz-
matske vrijednosti adropina bile značajno povišene (p=0,003). Zamijećeno je sniženje vrijednosti inzulina natašte (sa 
17,79±6,53 na 13,38±3,51 mU/L, p=0,002), glukoze natašte (s 8,66±3,07 na 7,41±2,21 mmol/L, p=0,004) te HbA1c (sa 
7,98±0,70% na 7,26±0,36%, p=0,003). HOMA-IR se značajno smanjio (sa 7,30±5,19 na 4,52±2,61, p=0,002). Također su 
zabilježene niže vrijednosti sistoličkog arterijskog tlaka, bolji lipidni profil te poboljšanje jetrene i bubrežne funkcije, iako ne 
statistički značajno. Primjena liraglutida u pretilih muškaraca koji boluju od ŠBT2 rezultira statistički značajno višim razina-
ma plazmatskog adropina, značajnim smanjenjem tjelesne težine i poboljšanjem svih parametara inzulinske rezistencije, tj. 
sniženjem plazmatskog inzulina i glukoze natašte te nižim HOMA-IR.
Ključne riječi: Šećerna bolest tip 2; Inzulinska rezistencija; Pretilost; Adropin; Liraglutid; Endotelna disfunkcija
